Coblopasvir - Beijing Kawin Technology
Alternative Names: cyberway; KW-136Latest Information Update: 25 Feb 2022
Price :
$50 *
At a glance
- Originator Beijing Kawin Technology Share-Holding
- Class Antivirals; Carbamates; Dioxolanes; Imidazoles; Pyrrolidines; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis C
Most Recent Events
- 25 Feb 2022 No development reported - Phase-III for Hepatitis C treatment (Combination therapy) in China (PO) (Beijing Kawin Technology Share-Holding pipeline, February 2022)
- 11 Feb 2020 Launched for Hepatitis C treatment (Combination therapy) in China (PO)
- 11 Feb 2020 Registered for Hepatitis C treatment (Combination therapy) in China (PO) (ADNM) Request sent